Skip to content

Randomized controlled clinical study on inhaling the recombinant human interferon a1b for the treatment of the viral pneunonia in children

Randomized controlled clinical study on inhaling the recombinant human interferon a1b for the treatment of the viral pneunonia in children

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003065
Enrollment
Unknown
Registered
2013-02-18
Start date
2013-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the viral pneunonia

Interventions

control group:ribavirin
inhaling treatment group:inhaling treatment

Sponsors

Guangzhou Woman and Children medical center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 5 Years

Inclusion criteria

Inclusion criteria: 1. aged 1 month to 5 years; 2. the children has been diagnosed as the viral pneumonia and need to be in hospital; 3. the acute period, phase time<=72 hrs;

Exclusion criteria

Exclusion criteria: 1. the severe type of the viral pneumonia, included: 1) SaO2<=0.92; 2) shock and disturbance of consciousness; 3) the rate of the breathe increase quickly, the fast pulse rate with Serious respiratory distress and depletion; 4) refractory apnea or Slow and irregular breathe; 2. the poor development in bronchial and lung of children; 3. bave used Corticosteroids and other immunity regulator in 2 weeks before adminitrated in hospital; 4. sensitive to the interferon; 5. children suffering congenital heart disease, liver disease, kideny disease and Hematopoietic system disease, epilessy and other central nervous system disorder.

Design outcomes

Primary

MeasureTime frame
the cure rate;the average hospital time;the change of the signs in lung;

Countries

China

Contacts

Public ContactDeng Li
47125358@qq.com+86 0755 26549194

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026